The Continuation Appointment: How NHS Clinics Decide Whether Your GLP-1 Prescription Carries On

The appointment nobody warns you about

Most patients spend weeks, sometimes months, clearing the hurdles that stand between them and a first GLP-1 prescription. Referral thresholds, blood tests, conversations with a practice nurse, the wait for a tier 3 weight management service. The injection itself can feel like the finish line.

It is not. Under NHS arrangements, a GLP-1 medicine for weight management is prescribed as part of a monitored course of treatment, and that course is subject to review. In most English services the first formal checkpoint arrives somewhere between three and six months after treatment begins, with a further decision at the twelve-month mark. As of 2026, this remains the standard pattern across NHS weight management pathways, although the exact timing and paperwork vary between Integrated Care Boards and providers.

The review is not designed to catch people out. Its purpose is to confirm that a costly, injectable medicine is doing what it was prescribed to do, that it is being tolerated, and that the person receiving it is deriving genuine benefit. Understanding how the decision is made is the surest way to arrive at the appointment prepared rather than anxious.

Why the six-month mark matters

NICE guidance for the GLP-1 medicines licensed for weight management is explicit that treatment should not continue indefinitely by default. For semaglutide, guidance issued in 2023 set out that treatment should be stopped if a patient has not lost at least 5% of their starting body weight after six months on the maintenance dose. Comparable continuation criteria apply to tirzepatide and to liraglutide, with the precise wording differing between products.

What that means in plain terms is that the review is a structured decision point, not a vague chat. The clinician is asked to weigh evidence of response against the criteria, and to record a rationale whichever way the decision falls. Patients who understand this in advance tend to find the process far less opaque.

What 'clinically significant' actually means

It is tempting to assume the review hinges on one number. In practice, the 5% threshold is a floor, not a ceiling, and it is only one item in a wider assessment. Clinicians working in tier 3 services typically consider:

• the percentage of starting body weight lost, calculated from a documented baseline rather than a remembered figure;
• change in waist circumference, which can move even when the scales stall;
• blood pressure readings taken across the treatment period;
• HbA1c and lipid results, particularly where type 2 diabetes or cardiovascular risk formed part of the original referral;
• improvements in sleep apnoea symptoms, joint pain, mobility or breathlessness;
• liver function markers where metabolic liver disease was a concern;
• and the patient's own account of appetite, eating patterns, energy and quality of life.

A patient who has lost 4% but whose blood pressure has fallen, whose sleep has improved and who has sustained a genuine change in eating behaviour is in a very different position from one who has lost 4% and abandoned the dietitian appointments. Reviewers are asked to exercise clinical judgement, and that judgement draws on the whole picture.

Assembling your evidence before the appointment

NHS clinics hold their own records, but gaps are common. Weight entries get missed, blood tests are taken at a different practice, and the patient's own experience of the previous six months is rarely captured in a clinical note. Arriving with an organised folder, paper or digital, makes a material difference.

Worth bringing:

1. A dated weight record. Weigh-ins taken on the same scales, at roughly the same time of day, ideally with the baseline recorded at the point of first prescription. A handful of readings across the period is more persuasive than a single figure on the day.
2. An injection diary. Dates, doses and any missed weeks. Adherence is one of the first things a reviewer will check when response has been modest.
3. A side-effect log. Nausea, constipation, fatigue, reflux, injection-site reactions, and whether they resolved or forced a dose reduction.
4. Recent blood tests and home readings. If your GP practice has carried out bloods, ask for the results to be shared with the weight management service in advance.
5. A complete medicines list. Including over-the-counter preparations and anything prescribed elsewhere. Some common medicines, including certain steroids, antipsychotics and antidepressants, work against weight loss, and a reviewer needs to know about them.
6. A short written note. Half a page on what has changed: what you eat now, how you feel, what has been difficult. It saves time and ensures your perspective is on the record.

If the scales have barely moved

A disappointing weigh-in is not automatically the end of treatment. Before concluding that the medicine has failed, a clinician will usually work through a series of explanations: the dose may not yet have been optimised, injections may have been missed or given incorrectly, constipation may be masking loss, another medicine may be contributing, or expectations may not have been calibrated at the outset.

In some cases the answer is a dose adjustment or a switch to a different GLP-1 medicine within its licensed criteria. In others, the honest conclusion is that the treatment is not delivering enough benefit to justify continuing, and the conversation turns to stopping safely and to what happens next. Neither outcome is a judgement on the patient.

How NHS monitoring differs from private care

Private prescribing has expanded considerably and now accounts for a substantial share of GLP-1 use in the UK. Monitoring arrangements, however, are not equivalent. NHS tier 3 services typically provide multidisciplinary input, with dietetic, psychological and medical involvement, structured reviews, and blood monitoring built into the pathway.

Private providers vary widely. Some offer robust follow-up with a named prescriber and regular bloods; others rely on an online questionnaire and a photograph of the scales. If you are privately prescribed, it is worth asking explicitly what the review process looks like, who conducts it, and whether your GP is kept informed. Continuity of care matters more than the convenience of a same-day prescription.

After the decision

The most common outcome is straightforward: continue, with a further review date set. Sometimes the dose changes, or the review interval shortens. Occasionally treatment stops, and a sensible service will pair that with a maintenance plan covering nutrition, activity and follow-up.

Whatever the result, the appointment is a checkpoint rather than a verdict. Arriving with clear records, an honest account of the past six months and a willingness to discuss what has and has not worked will give you the best chance of a decision that reflects your actual circumstances.